It would dovetail very nicely with their Sigma-Aldrich purchase, and is eminently do-able.
Not my favored scenario; just makes sense. My guess is they would pay $85 -$92/share.
Solid & broad patent portfolio, uninspired/weak share price, lots of cash suggests that OLED is likely to draw suitors. Aging management likely to be receptive when weighing the risks of what many view as a topping market.I would not be surprised to see a bid for OLED ahead of the election. A prospective suitor won't wait until OLED is firing on all cylinders.
Mea culpa! I based my comment on numbers provided without proper context. Congratulations to NEO on their continued outstanding performance! Again, my apologies for previous & hasty post.
For those of you who follow medical/biotech area, you might want to take a look at NEO. Rapidly growing
diagnostic lab (cancer) company that is firing on all cylinders & largely unknown at the retail level. Compelling story. As always, conduct your own due diligence & come to your own conclusions.